Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Immunity
|
July 21, 2017
Interleukin-7 Availability Is Maintained by a Hematopoietic Cytokine Sink Comprising Innate Lymphoid Cells and T Cells
Christopher E Martin, Darina S Spasova, Kwesi Frimpong-Boateng, et al.
Blood
|
April 24, 2013
IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R
Christopher E Martin, Ester M M van Leeuwen, Se Jin Im, et al.
Nature Communications
|
April 20, 2016
Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans
Felix Broecker, Jonas Hanske, Christopher E Martin, et al.
ACS Chemical Biology
|
November 7, 2019
Synthetic Oligosaccharide-Based Vaccines Protect Mice from <i>Clostridioides difficile</i> Infections
Felix Broecker, Erik Wegner, Bruna M S Seco, et al.
Scientific Reports
|
February 5, 2016
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Uwe Möginger, Anja Resemann, Christopher E Martin, et al.
Scientific Reports
|
August 3, 2016
The aged lymphoid tissue environment fails to support naïve T cell homeostasis
Bryan R Becklund, Jared F Purton, Chris Ramsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Susan Slovin, Xin Gao, Xiao X Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 24, 2019
Microbe-focused glycan array screening platform
Andreas Geissner, Anika Reinhardt, Christoph Rademacher, et al.
Nature Communications
|
November 24, 2025
T<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
Hubert Tseng, Bhagirathbhai Dholaria, Stacey A Cranert, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Immunity
|
July 21, 2017
Interleukin-7 Availability Is Maintained by a Hematopoietic Cytokine Sink Comprising Innate Lymphoid Cells and T Cells
Christopher E Martin, Darina S Spasova, Kwesi Frimpong-Boateng, et al.
Blood
|
April 24, 2013
IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R
Christopher E Martin, Ester M M van Leeuwen, Se Jin Im, et al.
Nature Communications
|
April 20, 2016
Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans
Felix Broecker, Jonas Hanske, Christopher E Martin, et al.
ACS Chemical Biology
|
November 7, 2019
Synthetic Oligosaccharide-Based Vaccines Protect Mice from <i>Clostridioides difficile</i> Infections
Felix Broecker, Erik Wegner, Bruna M S Seco, et al.
Scientific Reports
|
February 5, 2016
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Uwe Möginger, Anja Resemann, Christopher E Martin, et al.
Scientific Reports
|
August 3, 2016
The aged lymphoid tissue environment fails to support naïve T cell homeostasis
Bryan R Becklund, Jared F Purton, Chris Ramsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Susan Slovin, Xin Gao, Xiao X Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 24, 2019
Microbe-focused glycan array screening platform
Andreas Geissner, Anika Reinhardt, Christoph Rademacher, et al.
Nature Communications
|
November 24, 2025
T<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
Hubert Tseng, Bhagirathbhai Dholaria, Stacey A Cranert, et al.
Page
of 2